Basel headquartered Nouscom is developing cancer vaccines with a platform that enables it to pack a high number of neoantigens into its product candidates

blonca9
Sep 25, 2024
1 min read

CEO Marina Udier describes how the company is developing an off the shelf product that includes over 200 neoantigens, a personalized product with 60 neoantigens, and is also developing a vaccine that is meant to prevent the occurrence of cancer in Lynch Syndrome carriers.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Basel headquartered Nouscom is developing cancer vaccines with a platform that enables it to pack a high number of neoantigens into its product candidates

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight